Towards Rational Cancer Therapeutics: Optimizing Dosing, Delivery, Scheduling, and Combinations
- 1 September 2020
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 108 (3), 458-470
- https://doi.org/10.1002/cpt.1954
Abstract
The current trend to personalize anticancer therapies mostly relies on selecting the best drug or combination of drugs to achieve optimal efficacy in patients. In addition to the comprehensive genetic and molecular knowledge of each tumor before choosing the drugs to be given, there is probably much room left for improvement by further personalizing the very modes by which the drugs are given, once they have been carefully selected. In particular, shifting from standard dosing to tailored dosing should help in maintaining drug exposure levels in the right therapeutic window, thus ensuring that the efficacy/toxicity balance is optimal. This paper covers the current knowledge regarding pharmacokinetic/pharmacodynamic relationships of anticancer agents, from decades-old cytotoxics to the latest immune checkpoint inhibitors, the most frequent sources for long-neglected interpatient variability impacting on drug exposure levels, and what could be done to achieve real personalized medicine in oncology such as implementing therapeutic drug monitoring with adaptive dosing strategies or using model-driven modalities for personalized dosing and scheduling.This publication has 113 references indexed in Scilit:
- Model‐based design of rituximab dosage optimization in follicular non‐Hodgkin's lymphomaBritish Journal of Clinical Pharmacology, 2012
- Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancerBritish Journal of Cancer, 2011
- Predictive, personalized, preventive, participatory (P4) cancer medicineNature Reviews Clinical Oncology, 2011
- Factors for Hematopoietic Toxicity of Carboplatin: Refining the Targeting of Carboplatin Systemic ExposureJournal of Clinical Oncology, 2010
- Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741Journal of Clinical Oncology, 2010
- A Universal Formula Based on Cystatin C to Perform Individual Dosing of Carboplatin in Normal Weight, Underweight, and Obese PatientsClinical Cancer Research, 2009
- Advances in Cancer TherapeuticsClinical Pharmacology & Therapeutics, 2009
- Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel and nab-PaclitaxelClinical Cancer Research, 2008
- Individual Fluorouracil Dose Adjustment Based on Pharmacokinetic Follow-Up Compared With Conventional Dosage: Results of a Multicenter Randomized Trial of Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- The use of the Calvert formula to determine the optimal carboplatin dosageZeitschrift für Krebsforschung und Klinische Onkologie, 1995